Denosumab Use in Myeloma Soars for No Obvious Reason

]]>(MedPage Today) -- Since its approval for patients with multiple myeloma in early 2018, uptake of denosumab (Xgeva) has been rapid, with a new study reporting the drug now reaching almost 40% of the bone-modifying market for this disease.Of 15...